Search Results
Your search for ,kEY matches 7151 pages
Showing 951 - 1000Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?
In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...
Combination of Immunotherapies for Advanced HPV-Associated Cancers
In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...
MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma
In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...
Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
Overcoming Resistance to KRAS G12C Inhibitors in Pancreatic and Colorectal Cancers
A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...
MSTFCRC Updates Recommendations for Colonoscopy Preparation
Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...
Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas
Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...
Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC
Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...
Clinical Characteristics of Breast Cancer in Young BRCA Carriers
In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...
Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...
Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
Palbociclib Plus Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative Metastatic Breast Cancer
In an overall survival analysis of a South Korean phase II trial (Young-PEARL) reported in The Lancet Oncology, Ahn et al found no benefit with palbociclib plus exemestane and leuprorelin vs capecitabine in premenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast...
The Importance of Diversity in Clinical Research
The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases. Study Details In the open-label multicenter study, 63...
ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...
Overall Survival and HRQOL with Addition of [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early HER2-Positive Breast Cancer
In an analysis from the ShortHER trial reported in JAMA Oncology, Dieci et al identified 10-year outcomes with 9 weeks or 1 year of adjuvant trastuzumab plus chemotherapy according to level of tumor-infiltrating lymphocytes (TILs) in patients with early HER2-positive breast cancer. Study Details...
Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...
BRCA1 Gene Mutations May Not Be Key to Prostate Cancer
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
Evaluation of Surrogate Endpoints for Overall Survival in Neoadjuvant Randomized Trials in Early Breast Cancer
In a study reported in Journal of Clinical Oncology, Conforti et al found that invasive disease–free survival with sufficient follow-up may be the best surrogate for overall survival in neoadjuvant randomized trials in early breast cancer. Study Details The study involved 11 trials with 15...
Immunotherapy for Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
In a single-center retrospective study reported in JAMA Oncology, Lochrin et al identified activity of ipilimumab/nivolumab in melanoma brain metastases after progression on anti–PD-1 treatment. Study Details The study involved 28 patients with prior PD-1 inhibitor treatment who developed...
Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...
Darolutamide in Triple-Negative, AR-Positive Advanced Breast Cancer
In a French phase II trial (UCBG 3-06 START) reported in The Lancet Oncology, Bonnefoi et al found that treatment with the antiandrogen darolutamide did not reach the clinical benefit endpoint in patients with triple-negative, androgen receptor (AR)-positive advanced breast cancer. Triple-negative...
Cryotherapy With Taxane Infusion: Strategy for Preventing Peripheral Neuropathy in Breast Cancer
In a meta-analysis reported in the journal Breast Cancer Research and Treatment, Kumar et al found that the use of cryotherapy decreased the incidence of moderate or worse peripheral neuropathy by more than 50% in patients with breast cancer who received paclitaxel or nab-paclitaxel. Cryotherapy...
Betty Hamilton, MD: Research Highlights in GVHD
Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.
Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Locally Advanced Gastric Cancer: Adjuvant or Perioperative Therapy With D2 Resection
As reported in The Lancet Oncology by Zhang et al, final outcomes of the Chinese phase III RESOLVE trial showed improved overall survival with adjuvant S-1 and oxaliplatin (SOX) and perioperative SOX vs adjuvant capecitabine/oxaliplatin (CapOx) in patients with locally advanced gastric or...
Novel CD19-1XX CAR With Calibrated Signaling in LBCL
In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Untreated CLL: Acalabrutinib Combinations vs Chemoimmunotherapy
As reported in The New England Journal of Medicine by Jennifer Brown, MD, and colleagues, the phase III AMPLIFY trial found that fixed-duration acalabrutinib combined with venetoclax or venetoclax/obinutuzumab improved progression-free survival vs chemoimmunotherapy in fit, previously untreated...
Mantle Cell Lymphoma: Addition of Venetoclax to Ibrutinib
As reported in The Lancet Oncology by Michael Wang, MD, and colleagues, the phase III SYMPATICO trial has shown that venetoclax/ibrutinib significantly improved progression-free survival vs placebo/ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL). Study Details In the...
Merkel Cell Carcinoma: Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Disease
As reported in the Journal of Clinical Oncology by Bhatia et al, nivolumab/ipilimumab did not produce better outcomes vs nivolumab alone in a cohort of immune checkpoint inhibitor (ICI)-naive patients with recurrent or metastatic Merkel cell carcinoma (MCC) enrolled in the phase I/II CheckMate 358...
Potential Benefit of Consuming Yogurt in Decreasing the Risk of Certain Types of Colorectal Cancers
Long-term yogurt intake may protect against the development of colorectal cancer through changes in the gut microbiome, according to a recent study published by Ugai et al in Gut Microbes. Background Yogurt—which contains live strains of bacteria—is thought to protect against many types of...
Annual vs Less Frequent Mammographic Surveillance in Breast Cancer Patients Aged ≥ 50 Years
In a UK phase III noninferiority trial (Mammo-50) reported in The Lancet, Dunn et al found that less frequent mammographic surveillance was noninferior to annual surveillance in outcomes among patients with breast cancer aged 50 years or older. Study Details In the multicenter trial, 5,235 women...
Association of Acute and Late Toxicity in Radiotherapy for Prostate Cancer
In an individual patient data meta-analysis reported in The Lancet Oncology, Nikitas et al found that early toxicity associated with radiotherapy for prostate cancer was associated with increased risk for late toxicity. Study Details The study included patient-level data from six randomized phase...
Baseline Liquid Biopsy vs Tissue-Based Findings in Metastatic Colorectal Cancer
In an analysis reported in the Journal of Clinical Oncology, Stintzing et al found that baseline liquid biopsies identified RAS and BRAF mutations in patients with metastatic colorectal cancer considered RAS wild-type on the basis of tissue analyses. Study Details The study included patients from...
Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer
The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...
Felix Feng, MD, Leader in Genitourinary Cancer, Dies at Age 48
NRG Oncology, the RTOG Foundation, and the University of California, San Francisco (UCSF), announced the death of Felix Feng, MD, from cancer at age 48 on December 10, 2024. Dr. Feng was a George and Judy Marcus Distinguished Professor; Professor of Radiation Oncology, Urology and Medicine; Vice...
ARIEL4: Rucaparib vs Chemotherapy for Relapsed Ovarian Cancer With Deleterious BRCA1 or BRCA2 Mutations
In an article in The Lancet Oncology, Oza et al presented the final overall survival analysis of the phase III ARIEL trial of rucaparib vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma. Study Details In the open-label trial, 349 patients from sites in 12...
ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
ASCO has updated its guidelines on the role of neoadjuvant chemotherapy for patients newly diagnosed with advanced ovarian cancer, underscoring key considerations in selecting patients for treatment and where to go from there.1 Since ASCO’s previous guidelines were published in 2016, there has been ...
Intratumoral Injection of mRNA-2752 and Pembrolizumab in High-Risk DCIS
In a single-institution phase I trial reported in JAMA Oncology, Ramalingam et al found that intratumoral injection of pembrolizumab and mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs) was active in patients with high-risk ductal carcinoma in situ (DCIS). Study Details Ten ...
Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...
New Blood-Based Screening Test Accurately Detects Colorectal Cancer Risk in Adults Aged 45 and Older
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.1 Although screening for colorectal cancer through colonoscopy or sigmoidoscopy is effective in detecting the...
Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...
Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup
An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...
Weight Change and Heart Failure Risk After Breast Cancer Diagnosis
In a Republic of Korea nationwide cohort study reported as a research letter in JAMA Oncology, Jung et al found that weight increase following diagnosis of breast cancer was associated with increased risk of heart failure. Study Details The study used the National Health Insurance Service database...
Survey Finds More Than Half of Oncologists Are Experiencing Professional Burnout
In JCO Oncology Advances, Schenkel et al published the results of an ASCO survey measuring professional well-being, satisfaction, and the effect of both on career plans among oncologists in the United States. The analysis revealed a higher rate of burnout compared with that observed a decade ago....
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
